Table 1. Summary of responses to upfront three- and four-drug regimens with drugs that are approved for initial treatment.
| Regimen | Response | Reference | |
|---|---|---|---|
| VTD | 88% ⩾VGPR | 13% CR | 10 |
| VRD | 67% ⩾VGPR, 11% after four cycles | 39% CR+nCR, 6% after four cycles | 9 |
| VDR | 32% ⩾VGPR | 7% CR | 8 |
| VDC | 13% ⩾VGPR | 3% CR | 8 |
| DVD | 29%⩾VGPR | 20% CR | 2 |
| CyBorD | 60–65%⩾VGPR | 41% CR+nCR | 11, 12 |
| VCD then VTD | 57% ⩾VGPR | 26% CR | 1 |
| CRD | 30%⩾VGPR | 2% CR+nCR | 12 |
| CRd | 47%⩾VGPR, 30% after four cycles | 2% CR | 13 |
| RVDD | 57% ⩾VGPR (four cycles) | 35% CR+nCR | 7 |
| VDCR | 58% ⩾VGPR | 5% CR | 8 |
| CVDD | 88%⩾VGPR high risk and 63% std risk | 26% CR | 6 |
| BCDD | 40% ⩾VGPR (four cycles) | 10% CR (15% CR+nCR) (four cycles) | Current study |
Abbreviations: C, cyclosphamide; CR, complete response; D, dexamethasone (or pegylated liposomal doxorubicin in DVD); R, lenalidomide; T, thalidomide; V or B or Bor, bortezomib; VGPR, very good partial response.